Targeting Trx1 for cancer therapy and as prognostic marker of HCC has been considered because of the observed relationship between Trx1 expression and tumor aggressiveness, although the mechanisms underlying this association are still not well known [19]. This evidence concerns the gene TXN and hepatocellular carcinoma.